Hirschey Lab
About
The Hirschey Lab in the Departments of Medicine and Pharmacology & Cancer Biology and the Sarah W. Stedman Nutrition & Metabolism Center at Duke University explores different aspects of the biology of mitochondrial energy production, a crucial cellular process gaining recognition as an important regulator of human health and disease.
curator's ǝpoɔ
Scientific Advice
This "How to:" series provides scientific advice for scientists-in-training, such as under-graduate students, graduate students, and post-doctoral fellows.
README
This collection of papers provides valuable scientific advice from some of the world's leading scientists on scientific problem solving and communication
Dec 2012
Oct 2011
May 2011
Feb 2011
Feb 2010
Jan 2010
Nov 2012
Oct 2012
Sep 2012
Aug 2012
Jul 2012
Jun 2012May 2012
Apr 2012Mar 2012
Feb 2012Jan 2012
Dec 2011
Nov 2011Oct 2011
Sep 2011
Aug 2011Jul 2011
Jun 2011May 2011
Apr 2011
Mar 2011Feb 2011
Jan 2011
Dec 2010
Nov 2010
Oct 2010
Sep 2010
Aug 2010
Jul 2010
Jun 2010
May 2010
Apr 2010
Mar 2010Feb 2010
Jan 2010
- acetylation
- ada
- advice
- art
- beaver
- brainpicker
- calorie restriction
- career
- charisma
- communication
- crowdsourcing
- culture
- data
- definition
- diabetes
- duck
- energy
- funding
- grants
- hdac
- high-fat diet
- humor
- iamscience
- infographic
- key
- metabolic syndrome
- metabolism
- Nature
- obesity
- omnibus
- open science
- path
- platypus
- presentation
- publishing
- science
- science 2.0
- seminar
- SIRT3
- snarky
- summary
- technology
- two things
- TZD
- update
- venn diagram
- video
- Website
obesity
Dr. Hirschey presents at the UAB Nutrition Obesity Research Center
Dr. Hirschey presented today his current work on mitochondrial protein acylation and its regulation of metabolism at the National Obesity Research Center at the University of Alabama in Birmingham. Read More...Comments
Metabolic Homeostasis: HDACs Take Center Stage
Synthetic PPARg ligands (such as TZDs) are currently the most powerful insulin sensitizers in the treatment of type 2 diabetes in clinics. Of two TZD-based medicines (rosiglitazone and pioglitazone), rosiglitazone was withdrawn in the European market last year and will be removed from pharmacy stores in US by this November. The rosiglitazone-associated heart failure is responsible for the end of its market performance in Europe and US. A potential side effect in bladder cancer is another threat to the value of TZD-based medicines for type 2 diabetes. Do scientist have any new leads towards drug targets/candidates to replace TZD-based medicines?
Read More...